Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$8.09 ▲ +0.23
(+2.93%)
MKT CAP: $499.2M • VOL: 679.7K
52W L $2 52W H $9
TKNO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $40.5M | $37.7M | $36.7M |
| YoY Revenue Growth % | +7.4% | +2.9% | — |
| Gross Profit | $13.4M | $7.2M | — |
| Gross Margin % | 33.2% | 19.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$17.0M | -$26.1M | -$35.6M |
| Operating Margin % | -41.9% | -69.3% | -80.0% |
| Net Income (GAAP) | -$17.3M | -$26.7M | -$36.8M |
| EBITDA (Normalized) | -$16.1M | -$25.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.6M | -$12.4M | -$18.8M |
| Capital Expenditures (CapEx) | $1.1M | $1.1M | — |
| Free Cash Flow (FCF) | -$9.8M | -$13.5M | -$18.8M |
| FCF Margin % | -24.2% | -35.8% | -51.3% |
| Return on Invested Capital (ROIC %) | -21.3% | -26.3% | — |
| Cash & Short-Term Equivalents | $5.9M | $3.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $68.8M | $82.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TKNO.